2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2878

Treating Axial Spondyloarthritis to Target: Influence of the Population Characteristics and Comorbidities in Reaching Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive Disease in a Cohort of Patients Treated with Tnfalpha Inhibitors Agents
Abstract Number: 1167

Treating Experimental Arthritis with Adenoviral Overexpression of IL-22 or with Blocking Antibodies Against Endogenous IL-22 Both Reduces Inflammation and Destruction
Abstract Number: 1364

Treating Experimental Arthritis with the Innate Immune Inhibitor IL-37 Reduces Joint and Systemic Inflammation
Abstract Number: 2241

Treating to Target in Gout: The Epidemiology of Serum Urate Measurement Among Patients with Incident Gout in Usual Care Settings in the United States
Abstract Number: 390

Treatment and Outcomes in Pediatric SLE Patients in South Africa
Abstract Number: 2341

Treatment of Gout with Pharmacological Vs. Non-Pharmacological Complementary Therapy in the U.S.: An Internet Survey
Abstract Number: 2576

Treatment of Inflammatory Arthritis with a Hybrid Compound, LLP2A-Ale, Can Prevent Joint Destruction
Abstract Number: 1989

Treatment of Refractory Non-Infectious Aortitis: Tocilizumab Compared to Antitnf Alfa Agents. Multicenter Study of 44 Patients
Abstract Number: 3198

Treatment of Rheumatoid Arthritis with an Anti-Tumor Necrosis Factor Agent or Tocilizumab As First Biologic Therapy in a Global Comparative Observational Study
Abstract Number: 497

Treatment Outcomes in Elderly Patients with Rheumatoid Arthritis: Results from a Nationwide Korean Biologics Registry
Abstract Number: 2937

Treatment Patterns Differ Based on Age of Systemic Lupus Erythematosus Onset: A Comparison of Azathioprine and Mycophenolate on the Prevention of Lupus Nephritis
Abstract Number: 1665

Treatment Patterns in Rheumatoid Arthritis after Methotrexate: Data from a Rheumatoid Arthritis Cohort
Abstract Number: 2861

Treatment Patterns of Subcutaneous Biologic Agent Use Among Patients with Ankylosing Spondylitis
Abstract Number: 429

Treatment Preferences of Patients with Early Rheumatoid Arthritis: A Discrete-Choice Experiment
Abstract Number: 431

Treatment Target in a Disease Activity Score Steered Treatment Protocol in Early Arthritis Patients: Low Disease Activity or Remission

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].